News | March 19, 2026
Alcon walks away from LENSAR deal after regulatory roadblock
At the center of the collapse is opposition from the Federal Trade Commission
At the center of the collapse is opposition from the Federal Trade Commission
The facility supports drug discovery, biomolecular research, and the development of next-generation diagnostics
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
The trial enrolled patients with stage IV pancreatic cancer, where median life expectancy is just 6 to 12 months
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Subscribe To Our Newsletter & Stay Updated
